“I Can Make Energy. I Just Can’t Get It Back.”

A few months ago a coach messaged me about an athlete whose situation could have described almost anyone training at a high level. Training was going well, sleep looked decent, and the nutrition was cleaner than most people manage in a lifetime. But recovery felt off. Not broken delayed.

The athlete could still produce force and grind through hard sessions. He just couldn’t get his nervous system back online afterward. Morning readiness drifted down week over week. Lactate sat elevated longer than it should have. The way he put it was more precise than most: “I can make energy. I just can’t seem to get it back.”

That line stuck with me, because it lands on a question cellular medicine keeps running into. What if the limiting factor isn’t the ability to produce energy, but the ability to restore balance once energy has been spent?

Most athletes treat fatigue as an energy deficit, and sometimes that’s exactly what it is. But often it’s a distribution problem. And in some cases what you’re really looking at is a redox bottleneck the cell sits in an over-reduced state, metabolic flexibility slows, substrate turnover lags, and recovery drags behind. The vocabulary is heavy; the experience is simple. You train hard, you should recover, and you don’t.

That gap is what led me to put together a small pilot framework something for coaches, clinicians, and curious athletes who’d rather think like investigators than collect supplements.

The hypothesis is plain. If an over-reduced phenotype is slowing lactate clearance and blunting vagal recovery, then improving NAD+ availability and mitochondrial efficiency should move two things you can actually measure: how fast lactate clears after a standardized sprint, and how well the nervous system recovers overnight, tracked through morning RMSSD. Read together, those two numbers tell a surprisingly complete story.

Picture a city emptying out after a big game. Tens of thousands of people leave at once, traffic stacks up, the roads choke. The interesting question was never whether the city can move people obviously it can. It’s how fast normal flow returns. Recovery works the same way. Training generates metabolic traffic: lactate climbs, sympathetic drive climbs, fuel demand climbs. What matters is how quickly order comes back once the session is over.

That’s what makes lactate so useful. For years it got written off as a waste product, but that’s not what it is. Lactate is a shuttle a transport molecule that moves energy between tissues and does real work in normal metabolism. The molecule itself is rarely the problem. The problem shows up when clearance slows down. When lactate stays elevated longer than a known workload should produce, it can point to impaired mitochondrial oxidation, a shifted NAD+/NADH ratio, reduced pyruvate entry into the mitochondria, or some mix of those. That’s a mechanistic inference, not a diagnosis but it’s a useful clue. On the ground it feels like recovery debt piling up. The athlete still performs; he just stops bouncing back.

RMSSD covers the other half. It’s a practical window into parasympathetic recovery not a direct readout of vagal tone, but a reasonable reflection of how well the nervous system returns to a recovery state. And the lived version is familiar to anyone: some mornings you wake up ready, some mornings you don’t. The number just gives that feeling a shape. When lactate clearance and RMSSD start improving together, it’s a strong sign something real is shifting underneath. The traffic is clearing faster and the roads are opening sooner.

The pilot starts with restraint, and that part isn’t optional. The most common mistake I see is stacking six interventions before collecting six days of baseline. So the first phase is deliberately boring: fourteen days of morning RMSSD on the same device, same time, same position, plus two standardized sprint sessions a few days apart with capillary lactate measured before, three minutes after, and ten minutes after. If a clinician’s available, pull a fasting NAD panel and basic safety labs, run a resting ECG, and track blood pressure and resting heart rate. Nothing exotic just enough to set a reference point. Skip the reference point and every intervention afterward becomes a story you tell yourself.

The first intervention phase is all behavior. Sleep regularity, morning light, consistent training, breath work, enough protein, mineral sufficiency, less alcohol. People skip these because they’re familiar, but the cell doesn’t care whether a signal comes from a supplement bottle or from sunrise it only responds to the signal. The point of this phase is to strip out noise. If recovery improves here, that’s worth knowing. If it doesn’t, the next phase gets much easier to read.

Phase two brings in a clinician-guided NAD+ precursor. The marketing around NAD is loud, but the biology is simple: NAD+ sits at the center of cellular energy transfer. Every time fuel is oxidized, every time electrons move through a metabolic pathway, every time mitochondria handle substrate, NAD+ is in the middle of it. When availability drops, metabolic flexibility can drop with it, mitochondrial signaling can suffer, and recovery gets less efficient which, lived from the inside, feels like being metabolically stuck. The goal here isn’t to crown a particular precursor. It’s to change one variable and watch what happens. Lactate testing repeats every two weeks, RMSSD keeps running daily, and subjective recovery gets tracked throughout.

Not everyone responds, and that’s the point biology isn’t obligated to confirm what we expect. But when there is a response, it tends to look a certain way: lactate falls faster between minute three and minute ten, RMSSD trends up, recovery improves, and the athlete says some version of “I’m getting myself back faster.” I take that sentence seriously. The body registers recovery before the spreadsheet does; the spreadsheet just confirms it.

An optional third phase adds mitochondrial peptide support under clinical supervision. Molecules like SS-31 are interesting because they target cardiolipin, a phospholipid found only in the inner mitochondrial membrane that acts almost like scaffolding for the electron transport chain. When cardiolipin integrity slips, electron transfer gets less efficient, ATP production gets less coordinated, reactive oxygen species can rise, and recovery becomes more expensive to pay for. That’s the athlete who can still perform but takes a bigger hit doing it.

Peptides come last on purpose, because the hierarchy matters. You don’t bolt on a turbocharger before you’ve confirmed fuel reaches the engine. Establish behavioral stability, then look at NAD biology, then consider targeted mitochondrial support. Run it in that order and everything downstream gets easier to interpret.

The subjective data deserves respect the whole way through — perceived recovery on waking, breathlessness after hard efforts, sleep continuity, how long soreness lingers, the “snap” athletes talk about. These are imperfect, but they’re still data. The trick is collecting them consistently, and a simple zero-to-ten scale every morning usually does the job. No drama, just observation. The objective side carries equal weight: RMSSD rolling averages and coefficient of variation, lactate curves, resting heart rate, blood pressure, training outputs normalized to effort. None of those numbers means much alone. Together they form a pattern, and patterns are how cells actually talk. One lab value rarely explains physiology — relationships do. A lactate improvement with no HRV change tells one story; an HRV improvement with flat lactate tells another; both moving together is when I start trusting that something meaningful has shifted.

Safety sits over all of it. Set your stopping rules before you start: cardiac symptoms, new arrhythmias, unexpected lab abnormalities, a sustained drop in HRV, or lactate that climbs and won’t clear. Deciding those in advance takes the emotion out of the call and protects everyone involved.

One quiet benefit of running a small pilot is that it forces honesty. You can’t credit a supplement for gains that started before you introduced it, and you can’t blame a peptide for a bad week of sleep, an illness, or a stretch of travel. Context decides interpretation, and the structure of the pilot keeps the context in view.

The decision rules stay simple. If ten-minute lactate clearance improves meaningfully and RMSSD rises with no safety flags, the intervention probably helped. If the subjective side improves but the objective markers stay flat, watch longer before escalating. If both sides deteriorate, step back and reassess the whole system.

Notice what the framework never promises: certainty. Certainty is usually the first thing you lose once you start asking serious biological questions. What you get in return is better probability, evidence, direction, a sharper map. And plenty of other variables still live in the margins. Iron status shapes oxygen delivery. Thyroid function moves metabolic rate and autonomic output. Glycemic swings nudge HRV. Aggressive periodization can bury even healthy mitochondria. Immune activation can wear the mask of metabolic dysfunction. The pilot doesn’t erase any of that it just makes those factors easier to spot, which is the whole point. You’re not trying to prove a theory. You’re trying to learn something true.

The longer I coach and the more I sit with cellular medicine, the more the best coaches and the best clinicians seem to end up in the same place: they become systems thinkers. The body almost never speaks through one isolated pathway. Lactate, HRV, NAD biology, the mitochondria they’re all part of one conversation, and the only real question is whether we’re measuring carefully enough to hear it. If recovery is ultimately just the rate at which biological traffic returns to flow after stress, it’s worth asking how many athletes have spent years trying to build a bigger city when the real problem was somewhere in the roads.

3 comments